| 2018-03-26 | class changed from unclassified to disease-causing and subclass to CFTR-RD-causing (Montpellier) |
| 2024-10-14 | Class updated from CFTR-RD-causing to likely benign |
| 2024-12-09 | Variant classified as likely benign on the basis of epidemiological data (in particular high frequency in the general population), the number and type of diagnosis for patients reported in CFTR-France and functional data |
Variant NM_000492.4:c.1327G>T
| Name | NM_000492.4:c.1327G>T | ||||
| Protein name | NP_000483.3:p.(Asp443Tyr) | ||||
| Genomic name (hg19) | chr7:g.117188812G>T UCSC | ||||
| Genomic name (hg38) | chr7:g.117548758G>T UCSC | ||||
| #Exon/intron | exon 10 | ||||
| Legacy Name | D443Y | ||||
| Class | likely benign | ||||
complex allele in 66.27% of patients associated with | WT sequence |
ACTTCTTGGTACTCCTGTCCTGAAA G ATATTAATTTCAAGATAGAAAGAGG |
Mutant sequence |
ACTTCTTGGTACTCCTGTCCTGAAA T ATATTAATTTCAAGATAGAAAGAGG |
|
| G576A | non disease-causing |
| R668C | non disease-causing |
| G576A ; R668C | non disease-causing |
| D443Y ; G576A ; R668C | disease-causing - CFTR-RD-causing |
![]() |
![]() | dbSNP rs147422190 |
![]() | ![]() |
| Reference | PMID | Splicing | mRNA level | Maturation | Localization | Channel fonction (Cl-) | Bicarbonate |
| El-Seedy et al, 2012 | 22678879 | ✓ | ✓ | ✓ |
« ✓ » indicates the type of analysis performed and not the results
| Modulator | FDA approval | EMA approval | in vitro / ex vivo data | clinical data |
| IVA | no | no | no | no |
| TEZ-IVA | yes | no | yes | no |
| ELX-TEZ-IVA | yes | no | yes | no |
| VNZ-TEZ-DIVA | yes | no | yes | no |
clinical and functional data presented above are provided by Vertex
No patient found in CFTR-NGS catalogue |
| TOTAL NUMBER OF PATIENTS | 83 |
|---|---|
| Asymptomatic compound heterozygote | 5 |
| CF | 1 |
| CFTR-RD | 74
|
| Pending | 2 |
| Pending non-CF | 1 |
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| Phenotype | Patient ID | Variant status | Additional variants |
|---|---|---|---|
| CBAVD | 4752 | heterozygote | CF-causing- Undef |
| CBAVD | 2989 | heterozygote | CF-causing - Trans |
| CBAVD | 3335 | heterozygote | CF-causing - Trans |
| CBAVD | 5590 | heterozygote | CF-causing - Trans |
| CBAVD | 6458 | heterozygote | CF-causing- Undef |
| CBAVD | 5764 | heterozygote | CF-causing- Undef |
| CBAVD | 4646 | heterozygote | CF-causing - Trans |
| CBAVD | 2853 | heterozygote | CF-causing - Trans |
| CBAVD | 6223 | heterozygote | varying clinical consequence- Undef VUS3- Undef |
| CBAVD | 6389 | heterozygote | CF-causing - Trans |
| CBAVD | 2485 | heterozygote | CF-causing- Undef VUS3- Undef |
| CBAVD | 2756 | heterozygote | CF-causing- Undef |
| CBAVD | 2806 | heterozygote | CF-causing- Undef |
| CBAVD | 2824 | heterozygote | CF-causing- Undef |
| CBAVD | 5610 | heterozygote | CF-causing - Trans |
| CBAVD | 5943 | heterozygote | CF-causing- Undef |
| CBAVD | 4331 | heterozygote | CF-causing - Trans |
| CBAVD | 4534 | heterozygote | CF-causing- Undef |
| CBAVD | 4571 | heterozygote | CF-causing- Undef |
| CBAVD | 4574 | heterozygote | CF-causing- Undef |
| CBAVD | 4612 | heterozygote | CF-causing- Undef |
| CBAVD | 6471 | heterozygote | CF-causing- Undef |
| CBAVD | 6321 | heterozygote | CF-causing- Undef |
| CBAVD | 5947 | heterozygote | CF-causing- Undef |
| CBAVD | 4279 | heterozygote | CF-causing- Undef |
| CBAVD | 6318 | heterozygote | CF-causing- Undef |
| CBAVD | 6317 | heterozygote | CF-causing- Undef |
| CBAVD | 5882 | heterozygote | CF-causing - Trans |
| CBAVD | 4683 | heterozygote | CF-causing- Undef |
| CBAVD | 508 | heterozygote | CFTR-RD-causing - Trans |
| CBAVD | 511 | heterozygote | VUS3 - Trans |
| CBAVD | 549 | heterozygote | CF-causing- Undef |
| CBAVD | 556 | heterozygote | CF-causing- Undef |
| CBAVD | 658 | heterozygote | CF-causing- Undef |
| CBAVD | 659 | heterozygote | VUS3- Undef |
| CBAVD | 682 | heterozygote | CF-causing - Trans |
| CBAVD | 763 | heterozygote | CF-causing - Trans |
| CBAVD | 497 | heterozygote | CF-causing- Undef |
| CBAVD | 480 | heterozygote | CF-causing- Undef |
| CBAVD | 4722 | heterozygote | CF-causing- Undef |
| CBAVD | 4735 | heterozygote | varying clinical consequence - Trans |
| CBAVD | 395 | heterozygote | CF-causing - Trans |
| CBAVD | 404 | heterozygote | varying clinical consequence- Undef |
| CBAVD | 430 | heterozygote | CF-causing - Trans |
| CBAVD | 433 | heterozygote | CF-causing- Undef |
| CBAVD | 452 | heterozygote | CF-causing- Undef |
| CBAVD | 900 | heterozygote | CF-causing- Undef |
| CBAVD | 5665 | heterozygote | CFTR-RD-causing - Trans |
| CBAVD | 5463 | heterozygote | CF-causing - Trans |
| CBAVD | 1745 | heterozygote | CFTR-RD-causing- Undef |
| CBAVD | 1512 | heterozygote | CF-causing- Undef |
| CBAVD | 1510 | heterozygote | CF-causing- Undef |
| CBAVD | 1423 | heterozygote | CF-causing- Undef |
| CBAVD | 1381 | heterozygote | |
| CBAVD | 1365 | heterozygote | CF-causing- Undef |
| CBAVD | 1340 | heterozygote | CF-causing- Undef |
| CBAVD | 6341 | heterozygote | CF-causing- Undef |
| CBAVD | 5181 | heterozygote | CF-causing - Trans VUS3- Undef |
| CBAVD | 1248 | heterozygote | CF-causing- Undef |
| CBAVD | 1335 | heterozygote | CF-causing- Undef |
| Other | 4570 | heterozygote | CF-causing - Trans |
| Other | 4809 | heterozygote | CF-causing- Undef |
| Other | 4278 | heterozygote | CF-causing - Trans VUS1- Undef |
| Other | 5083 | heterozygote | CF-causing- Undef |
| Other | 5264 | heterozygote | CF-causing- Undef |
| Other | 5814 | heterozygote | CF-causing- Undef |
| Pending non-CF | 4825 | heterozygote | varying clinical consequence - Trans |
| CF | 5215 | heterozygote | CFTR-RD-causing- Undef |
| Bronchiectasis | 6282 | heterozygote | CF-causing - Trans |
| Bronchiectasis | 5669 | heterozygote | VUS3 - Trans |
| Bronchiectasis | 5126 | heterozygote | |
| Pancreatitis | 2338 | heterozygote | |
| Pancreatitis | 5740 | heterozygote | |
| Pancreatitis | 4996 | homozygote | c.1210-34_1210-6TG[11]T[5] - Trans c.1327G>T - p.(Asp443Tyr) - Trans |
| Pending | 2843 | heterozygote | CF-causing - Trans |
| Pending | 4304 | heterozygote | |
| CRS-NP | 3043 | heterozygote | CF-causing - Trans |
| Asymptomatic compound heterozygote | 3257 | heterozygote | CF-causing - Trans |
| Asymptomatic compound heterozygote | 5602 | heterozygote | VUS3 - Trans |
| Asymptomatic compound heterozygote | 4422 | heterozygote | VUS3 - Trans |
| Asymptomatic compound heterozygote | 5964 | heterozygote | CF-causing - Trans |
| Asymptomatic compound heterozygote | 4260 | heterozygote | CFTR-RD-causing - Trans |
| Aquagenic palmoplantar keratoderma | 6480 | heterozygote | CFTR-RD-causing- Undef |
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| CFTR variants are clustered into five groups (click here for more details about the classification of variants): |
|